In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5321-5327

  Al Saigh, R ^a   Elefanti, A ^a   Velegraki, A ^b   Zerva, L ^a   Meletiadis, J ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; DRUG EXPOSURE; DRUG HALF LIFE; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; PYRIMIDINES; TRIAZOLES;

EID: 84866324621     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00549-12     Document Type: Article

References (27)

1. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J. Antimicrob. Chemother. 59:230-237. (Pubitemid 47072062)
2. Baddley JW, et al. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47:3271-3275.
3. Bruggemann RJ, et al. 2008. Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30:403-411.
4. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard, 2nd ed, M38-A2, vol 28. CLSI, Wayne, PA.
5. Espinel-Ingroff A, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
6. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
7. Kontoyiannis DP, et al. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091-1100.
8. Li Y, et al. 2008. A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int. J. Antimicrob. Agents 31:369-374.
9. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
10. Mayr A, Lass-Florl C. 2011. Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature. Eur. J. Med. Res. 16:153-157.
11. Meletiadis J, et al. 2012. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 56:403-410.
12. Meletiadis J, te Dorsthorst DT, Verweij PE. 2003. Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi. J. Clin. Microbiol. 41:4718-4725. (Pubitemid 37259784)
13. Murphy M, Bernard EM, Ishimaru T, Armstrong D. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698. (Pubitemid 27098427)
14. Pascual A, et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
15. Pascual A, et al. 2007. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents Chemother. 51:137-143. (Pubitemid 46047698)
16. Patterson TF, et al. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore, MD) 79:250-260.
17. Pfaller M, et al. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49:586-590.
18. Purkins L, et al. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553. (Pubitemid 34793462)
19. Purkins L, et al. 2003. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl 1):2-9. (Pubitemid 37491727)
20. Scheven M, Schwegler F. 1995. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob. Agents Chemother. 39:1779-1783.
21. Snelders E, Melchers WJ, Verweij PE. 2011. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 6:335-347.
22. Steinbach WJ, et al. 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39:192-198. (Pubitemid 38971489)
23. Takemoto K, et al. 2009. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Chemotherapy 55:105-113.
24. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327-360. (Pubitemid 351265310)
25. Walsh TJ, et al. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319. (Pubitemid 36898165)
26. Warn PA, Sharp A, Denning DW. 2006. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 57:135-138. (Pubitemid 43057070)
27. Warn PA, et al. 2006. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58:1198-1207. (Pubitemid 44884139)